Foresite Capital Fund IV, L.P.'s Form 4 filing
Kinnate Biopharma Inc. (KNTE) · filed May 10, 2023
- Accession no.
- 0001209191-23-028527
- Filed
- May 10, 2023, 5:42 PM ET
- Trade date
- May 8, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $4.98M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foresite Capital Fund IV, L.P.CIK 0001704131 | 10% Owner |
| Foresite Capital Management IV, LLCCIK 0001704132 | 10% Owner |
| Foresite Capital Fund V, L.P.CIK 0001792204 | 10% Owner |
| Foresite Capital Opportunity Fund V, L.P.CIK 0001792205 | 10% Owner |
| Foresite Capital Management V, LLCCIK 0001792206 | 10% Owner |
| Foresite Capital Opportunity Management V, LLCCIK 0001792207 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2023 | Common Stock | PPurchaseAcquired | +1,550,956 | $2.80 | +$4,342,676.8 | 3,525,957 | Indirect | Duplicate filing |
| May 8, 2023 | Common Stock | PPurchaseAcquired | +229,044 | $2.80 | +$641,323.2 | 520,711 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 is one of two Form 4s filed on the date hereof in respect of these transactions. The Reporting Person for the other Form 4 is James B. Tananbaum.